Human Lumican Biotinylated Antibody Summary
Gln19-Asn338
Accession # P51884
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Lumican
Lumican is a 40 kDa member of the family of small leucine-rich repeat proteoglycans (SLRPs) and the class II subfamily (1). Human Lumican is synthesized as a 338 amino acid (aa) precursor that contains an 18 aa signal sequence and a 320 aa mature chain. The mature chain contains a negatively charged N-terminal domain containing sulfated tyrosine and disulfide bonds, 12 leucine-rich repeats (LRRs), four potential sites of N-linked glycosylation, and a carboxyl terminal domain containing two conserved cysteines (1). Mature human Lumican is 88%, 87%, and 70% aa identical to mature mouse, rat, and chick Lumican, respectively. SLRPs constitute an important fraction of noncollagenous extracellular matrix proteins (ECM) proteins (1, 2). Lumican is expressed in a variety of tissues, including skin, artery, lung, cornea, kidney, bone, aorta, and articular cartilage (1). Lumican's role in vivo has been found using Lumican null mice. These mice have functional deficits including corneal opacity as well as skin and tendon fragility associated with disorganized and loosely packed collagen fibers (1, 3‑6). The abnormal connective tissue phenotype seen in the Lumican null mice shows the importance of the role of Lumican in collagen fibrillogenesis (1). In addition to the control of collagen fibril assembly, Lumican has been shown to play a role in the regulation of cell proliferation (7, 8), migration (8, 9), and adhesion (9). Lumican's overexpression has been reported in carcinoid tumor, breast, colorectal, neuroendocrine, uterine cervical and pancreatic cancers (10).
- Nikitovic, D. et al. (2008) IUBMB Life 60:818.
- Blochberger, T.C. et al. (1992) J. Biol. Chem. 267:347.
- Chakravarti, S. et al. (1998) J. Cell Biol. 141:1277.
- Chakravarti, S. et al. (2000) Invest. Ophthalmol. Vis. Sci. 41:3365.
- Jepsen, K.J. et al. (2002) J. Biol. Chem. 277:35532.
- Chakravarti, S. et al. (2003) Invest. Ophthalmol. Vis. Sci. 44:2422.
- Vuillermoz, B. et al. (2004) Exp. Cell Res. 296:294.
- Nikitovic, D. et al. (2008) FEBS J. 275:350.
- D’Onofrio, M.F. et al. (2008) Biochem. Biophys. Res. Commun. 365:266.
- Ishiwata, T. et al. (2007) Oncol. Rep. 18:537.
Product Datasheets
Citation for Human Lumican Biotinylated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
Authors: Martin L. Decaris, Kelvin W. Li, Claire L. Emson, Michelle Gatmaitan, Shanshan Liu, Yenny Wang et al.
Hepatology
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human Lumican Biotinylated Antibody
Average Rating: 5 (Based on 1 Review)
Have you used Human Lumican Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
